Author Archives: Vigenius

Setting up your first bioprocessing space can be an intimidating task, especially if you have historically relied on traditional techniques for cell culture reactions, such as shake flasks.

To scale upstream bioprocesses, an effective scale-up strategy is required to ensure the reproducibility of both cell culture growth and batch yields at large working volumes.

Biosimilar Development is happy to usher in the new year with its third installment of the Editorial Board Q&A series. As you’ll read in the following responses, increased competition in 2021 is on the minds of many. Whether that competition is unlocked thanks to shared savings models, employer biosimilar initiatives, new/multiple product launches, and/or regulatory evolution, we just have to wait and see. But if one thing is clear, it’s that the industry has many exciting tools on the line that are worth watching as 2021 unfolds.

Besides building momentum against COVID-19, biopharma will accelerate its progress in genome editing, gene and cell therapy, synthetic biology, and other crucial areas.